Want to see CUPR full AI Analyst Report?
Cuprina Holdings (Cayman) Limited Class A (CUPR) AI Stock Analysis
Cuprina Holdings (Cayman) Limited Class A
(NASDAQ:CUPR)
The score is primarily constrained by weak financial performance—persistent losses, negative cash flow, and a sharp increase in 2025 cash burn—indicating elevated funding and execution risk. Technicals add downside pressure with the stock trading well below key moving averages and negative momentum indicators. Valuation provides limited offset because negative earnings make the P/E uninformative and there is no dividend support.
Cuprina Holdings (Cayman) Limited Class A (CUPR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 106.62K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 0.91
- Revenue Growth
- 6.30%
- EPS Growth
- -208.64%
- Country
- US
- Employees
- 10
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Cuprina Holdings (Cayman) Limited Class A Business Overview & Revenue Model
Company Description
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its fla...
Cuprina Holdings (Cayman) Limited Class A Financial Statement Overview
Summary
Overall financial profile is weak: revenue is small and volatile, profitability deteriorated sharply in 2025 (gross profit turned negative and losses widened), and operating/free cash flow are negative every year with a dramatic increase in 2025 cash burn. A partial offset is relatively modest debt and equity turning positive in 2025, but historical negative equity and ongoing cash burn elevate financing and execution risk.
Income Statement
18Very NegativeBalance Sheet
42NeutralCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 63.24K | 49.89K | 48.32K | 100.77K | 56.60K | 58.50K |
| Gross Profit | -16.63K | -645 | -3,024 | 36.60K | 19.98K | 23.06K |
| EBITDA | -6.19M | -4.56M | -1.43M | -994.12K | -1.06M | -489.44K |
| Net Income | -6.01M | -4.67M | -1.56M | -1.12M | -1.09M | -519.69K |
Balance Sheet | ||||||
| Total Assets | 8.50M | 8.50M | 1.75M | 1.59M | 1.44M | 953.05K |
| Cash, Cash Equivalents and Short-Term Investments | 3.12M | 3.12M | 116.47K | 35.26K | 564.58K | 767.29K |
| Total Debt | 482.72K | 482.72K | 254.79K | 121.82K | 183.63K | 170.03K |
| Total Liabilities | 3.45M | 3.45M | 6.20M | 4.48M | 3.21M | 1.64M |
| Stockholders Equity | 5.06M | 5.06M | -4.46M | -2.90M | -1.78M | -683.52K |
Cash Flow | ||||||
| Free Cash Flow | -16.46M | -9.19M | -1.26M | -1.61M | -1.87M | -224.72K |
| Operating Cash Flow | -16.37M | -9.13M | -1.24M | -1.54M | -1.85M | -221.86K |
| Investing Cash Flow | -87.19K | -58.23K | -21.88K | -67.98K | -31.28K | -2,860 |
| Financing Cash Flow | 21.04M | 12.23M | 1.34M | 1.08M | 1.68M | 991.39K |
Cuprina Holdings (Cayman) Limited Class A Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CUPR, the sentiment is Negative. The current price of 1.77 is below the 20-day moving average (MA) of 1.93, below the 50-day MA of 2.30, and below the 200-day MA of 3.02, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 40.25 is Neutral, neither overbought nor oversold. The STOCH value of 45.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CUPR.
Cuprina Holdings (Cayman) Limited Class A Risk Analysis
Cuprina Holdings (Cayman) Limited Class A disclosed 69 risk factors in its most recent earnings report. Cuprina Holdings (Cayman) Limited Class A reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksCuprina Holdings (Cayman) Limited Class A Peers Comparison
Overall Rating
HCWB42Neutral- CUPR41Neutral
CLDI38Underperform
GOVX38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HCWB | 42Neutral | $2.46M | -0.02 | -142.16% | ― | 707.02% | 70.52% |
| CUPR | 41Neutral | $10.43M | -1.18 | -84.78% | ― | 6.30% | -208.64% |
| CLDI | 38Underperform | $2.53M | -0.01 | -372.86% | ― | ― | 53.95% |
| GOVX | 38Underperform | $1.70M | -0.01 | -743.66% | ― | -100.00% | 77.63% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CUPR | Cuprina Holdings (Cayman) Limited Class A | 1.77 | -5.50 | -75.67% | |
| GOVX | Geovax Labs, Inc. | 0.17 | -14.18 | -98.83% | |
| HCWB | Hcw Biologics, Inc. | 1.10 | -20.50 | -94.91% | |
| CLDI | Calidi Biotherapeutics, Inc. | 0.69 | -23.79 | -97.19% | |
| PBM | Psyence Biomedical Ltd. | 3.31 | -15.44 | -82.35% | |
| ASBP | Aspire Biopharma Holdings, Inc. | 8.11 | -425.93 | -98.13% |
Cuprina Holdings (Cayman) Limited Class A Corporate Events
Cuprina Holdings Shareholders Approve Major Capital Increase and Governance Changes
Cuprina Holdings (Cayman) Limited reported that on October 15, 2026, shareholders at an extraordinary general meeting in Singapore and via webcast approved a major increase in the company’s authorised share capital from US$100,000 to US$10,000,...
Cuprina Holdings to Acquire Profitable Singapore Podiatry and Women’s Health Clinic Group
On October 1, 2026, Cuprina’s wholly owned BVI subsidiary signed agreements to acquire all shares of East Coast Podiatry Centre and Orchard Clinic Management for about S$4.0 million, via a mix of cash and Class A shares subject to lock-ups. Com...
Cuprina Holdings Closes Over-Allotment Option, Lifts Public Offering Proceeds to $5.7 Million
On September 29, 2026, Cuprina Holdings (Cayman) Limited closed the sale of 648,373 additional Class A ordinary shares at $1.15 per share, following the full exercise of the underwriter’s over-allotment option tied to its recent Nasdaq public o...
Cuprina Holdings Calls October EGM to Approve Major Share Capital Increase and Governance Changes
On September 18, 2026, Cuprina Holdings (Cayman) Limited filed a Form 6-K with the U.S. SEC announcing an extraordinary general meeting of shareholders scheduled for October 15, 2026 in Singapore and via webcast. Shareholders of record as of Septembe...
Cuprina Holdings Raises $4.97 Million in September Nasdaq Offering
On September 15, 2026, Cuprina Holdings (Cayman) Limited entered into an underwriting agreement with R. F. Lafferty & Co., Inc. for a Nasdaq-listed public offering of 4,322,489 Class A ordinary shares at $1.15 per share, raising gross proceeds of...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 11, 2026